Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

2008480 citationsJournal Article

Authors

Georgiana K. Ellis · Seattle Cancer Care Alliance

Henry G. Bone · Seattle Cancer Care Alliance

Rowan T. Chlebowski · Rocky Mountain Cancer Centers

Devchand Paul · Amgen (United States)

Silvana Spadafora · Rocky Mountain Cancer Centers

J. W. G. Smith · Rocky Mountain Cancer Centers

Michelle Fan

Abstract

In women with nonmetastatic breast cancer and low bone mass who were receiving adjuvant aromatase inhibitor therapy, twice-yearly administration of denosumab led to significant increases in BMD over 24 months at trabecular and cortical bone, with overall AE rates similar to those of placebo.

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 26, Issue 30, pp. 4875-4882

DOI: 10.1200/jco.2008.16.3832

Field-Weighted Citation Impact: 31.00